Brian Day
Concepts (583)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antioxidants | 47 | 2026 | 549 | 6.530 |
Why?
| | Oxidative Stress | 46 | 2026 | 1339 | 5.110 |
Why?
| | Glutathione | 31 | 2024 | 375 | 5.000 |
Why?
| | Metalloporphyrins | 27 | 2024 | 66 | 3.740 |
Why?
| | Mustard Gas | 8 | 2024 | 93 | 2.340 |
Why?
| | Reactive Oxygen Species | 23 | 2026 | 621 | 2.330 |
Why?
| | Particulate Matter | 5 | 2025 | 347 | 2.070 |
Why?
| | Thiocyanates | 6 | 2019 | 28 | 1.840 |
Why?
| | Bronchoalveolar Lavage Fluid | 15 | 2021 | 636 | 1.740 |
Why?
| | Chemical Warfare Agents | 5 | 2024 | 104 | 1.700 |
Why?
| | Lung | 24 | 2025 | 4109 | 1.640 |
Why?
| | Immunity, Innate | 4 | 2026 | 846 | 1.530 |
Why?
| | Lung Injury | 5 | 2024 | 237 | 1.510 |
Why?
| | Lung Diseases | 5 | 2026 | 787 | 1.420 |
Why?
| | ATP-Binding Cassette Transporters | 5 | 2012 | 118 | 1.240 |
Why?
| | Inflammation | 12 | 2025 | 2878 | 1.160 |
Why?
| | Smoking | 9 | 2015 | 1472 | 1.090 |
Why?
| | Animals | 75 | 2026 | 38058 | 0.910 |
Why?
| | Cyanides | 1 | 2026 | 56 | 0.900 |
Why?
| | Toll-Like Receptor 2 | 2 | 2025 | 126 | 0.890 |
Why?
| | Antidotes | 3 | 2016 | 145 | 0.870 |
Why?
| | Metabolic Networks and Pathways | 1 | 2026 | 187 | 0.860 |
Why?
| | Macrophages | 7 | 2025 | 1511 | 0.860 |
Why?
| | Mitochondria | 12 | 2026 | 984 | 0.850 |
Why?
| | Mesalamine | 2 | 2017 | 9 | 0.850 |
Why?
| | Flavonoids | 3 | 2011 | 87 | 0.810 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 4 | 2012 | 370 | 0.800 |
Why?
| | Berylliosis | 4 | 2017 | 202 | 0.790 |
Why?
| | Tumor Necrosis Factor-alpha | 7 | 2023 | 1217 | 0.780 |
Why?
| | Oxidation-Reduction | 15 | 2026 | 1087 | 0.770 |
Why?
| | Superoxide Dismutase | 13 | 2015 | 301 | 0.770 |
Why?
| | Cystic Fibrosis | 4 | 2020 | 1158 | 0.740 |
Why?
| | Pneumonia | 2 | 2020 | 631 | 0.730 |
Why?
| | Molecular Mimicry | 3 | 2008 | 37 | 0.670 |
Why?
| | Acetylcysteine | 5 | 2016 | 139 | 0.650 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2020 | 22 | 0.640 |
Why?
| | Interleukin-33 | 1 | 2020 | 45 | 0.640 |
Why?
| | Inhalation Exposure | 5 | 2016 | 115 | 0.640 |
Why?
| | Epithelial Cells | 10 | 2025 | 1125 | 0.620 |
Why?
| | Anti-Infective Agents | 2 | 2019 | 242 | 0.620 |
Why?
| | Thioredoxin-Disulfide Reductase | 3 | 2015 | 14 | 0.620 |
Why?
| | Mice | 38 | 2025 | 18339 | 0.610 |
Why?
| | Prodrugs | 1 | 2019 | 52 | 0.590 |
Why?
| | Chalcones | 5 | 2012 | 7 | 0.590 |
Why?
| | Neoplasm Proteins | 4 | 2014 | 442 | 0.580 |
Why?
| | Neuroprotective Agents | 5 | 2021 | 143 | 0.580 |
Why?
| | Influenza A virus | 3 | 2025 | 113 | 0.560 |
Why?
| | Allergens | 1 | 2021 | 384 | 0.550 |
Why?
| | Inflammation Mediators | 5 | 2018 | 509 | 0.550 |
Why?
| | Deoxyguanosine | 4 | 2016 | 25 | 0.550 |
Why?
| | Mice, Inbred C57BL | 19 | 2025 | 5992 | 0.550 |
Why?
| | Beryllium | 3 | 2009 | 161 | 0.530 |
Why?
| | Manganese | 5 | 2024 | 55 | 0.510 |
Why?
| | Cell Line | 13 | 2020 | 2882 | 0.500 |
Why?
| | Electronic Nicotine Delivery Systems | 3 | 2023 | 108 | 0.500 |
Why?
| | Anti-Bacterial Agents | 3 | 2019 | 1907 | 0.490 |
Why?
| | Organometallic Compounds | 2 | 2009 | 112 | 0.490 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 248 | 0.490 |
Why?
| | Free Radical Scavengers | 6 | 2013 | 82 | 0.490 |
Why?
| | Catalase | 4 | 2013 | 130 | 0.480 |
Why?
| | Wound Healing | 1 | 2019 | 351 | 0.480 |
Why?
| | Status Epilepticus | 4 | 2024 | 56 | 0.470 |
Why?
| | Industrial Waste | 1 | 2015 | 6 | 0.470 |
Why?
| | Immunity, Cellular | 1 | 2017 | 272 | 0.470 |
Why?
| | War Exposure | 1 | 2015 | 14 | 0.460 |
Why?
| | Reverse Transcriptase Inhibitors | 3 | 2004 | 87 | 0.460 |
Why?
| | Peroxidases | 1 | 2015 | 29 | 0.440 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2016 | 95 | 0.430 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 338 | 0.430 |
Why?
| | Lymphocytes | 3 | 2017 | 382 | 0.420 |
Why?
| | Hydrogen Peroxide | 6 | 2025 | 336 | 0.420 |
Why?
| | Respiratory Mucosa | 4 | 2011 | 322 | 0.420 |
Why?
| | NF-E2-Related Factor 2 | 2 | 2013 | 95 | 0.420 |
Why?
| | Respiratory System | 1 | 2015 | 149 | 0.410 |
Why?
| | Afghanistan | 4 | 2021 | 96 | 0.410 |
Why?
| | Skin | 3 | 2014 | 755 | 0.400 |
Why?
| | DNA, Mitochondrial | 5 | 2009 | 211 | 0.400 |
Why?
| | Rats | 20 | 2024 | 5597 | 0.390 |
Why?
| | Rats, Sprague-Dawley | 15 | 2024 | 2527 | 0.390 |
Why?
| | Humans | 59 | 2026 | 144759 | 0.390 |
Why?
| | Influenza, Human | 3 | 2025 | 616 | 0.390 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 5 | 2025 | 920 | 0.390 |
Why?
| | Cell Survival | 8 | 2014 | 1098 | 0.390 |
Why?
| | Cytokines | 8 | 2018 | 2061 | 0.380 |
Why?
| | Macrophages, Alveolar | 3 | 2011 | 368 | 0.380 |
Why?
| | Cell Proliferation | 6 | 2017 | 2496 | 0.370 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 2012 | 11 | 0.360 |
Why?
| | Signal Transduction | 8 | 2026 | 5226 | 0.360 |
Why?
| | Chemokines, CC | 1 | 2012 | 32 | 0.360 |
Why?
| | Pinocytosis | 1 | 2011 | 6 | 0.360 |
Why?
| | Glutathione Peroxidase | 2 | 2008 | 39 | 0.350 |
Why?
| | DNA | 4 | 2016 | 1463 | 0.350 |
Why?
| | Mice, Knockout | 11 | 2025 | 3121 | 0.350 |
Why?
| | Nerve Agents | 2 | 2024 | 7 | 0.350 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 474 | 0.350 |
Why?
| | Extracellular Space | 2 | 2011 | 120 | 0.350 |
Why?
| | Chalcone | 1 | 2011 | 2 | 0.350 |
Why?
| | Smoke | 3 | 2013 | 148 | 0.350 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 2 | 2011 | 153 | 0.340 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2011 | 139 | 0.340 |
Why?
| | Oxidants | 5 | 2019 | 103 | 0.330 |
Why?
| | Environmental Exposure | 1 | 2015 | 588 | 0.330 |
Why?
| | Membrane Transport Proteins | 1 | 2012 | 154 | 0.330 |
Why?
| | Macrophage Activation | 1 | 2011 | 193 | 0.320 |
Why?
| | Adaptation, Physiological | 2 | 2011 | 570 | 0.320 |
Why?
| | Virus Diseases | 2 | 2023 | 216 | 0.320 |
Why?
| | Sulfasalazine | 1 | 2009 | 22 | 0.310 |
Why?
| | Doxorubicin | 2 | 2011 | 397 | 0.310 |
Why?
| | Mitochondria, Liver | 3 | 2004 | 70 | 0.300 |
Why?
| | Chelating Agents | 1 | 2009 | 71 | 0.300 |
Why?
| | Prostaglandin D2 | 1 | 2009 | 22 | 0.300 |
Why?
| | Mitochondrial Diseases | 1 | 2009 | 93 | 0.290 |
Why?
| | Lung Neoplasms | 4 | 2011 | 2637 | 0.290 |
Why?
| | Mitochondrial Membranes | 1 | 2008 | 40 | 0.280 |
Why?
| | Adenosine Triphosphate | 2 | 2015 | 498 | 0.280 |
Why?
| | Apoptosis | 9 | 2015 | 2430 | 0.280 |
Why?
| | Male | 40 | 2025 | 72315 | 0.280 |
Why?
| | Pseudomonas Infections | 2 | 2015 | 221 | 0.280 |
Why?
| | Mycoplasma pneumoniae | 1 | 2008 | 53 | 0.270 |
Why?
| | NADPH-Ferrihemoprotein Reductase | 2 | 2005 | 10 | 0.270 |
Why?
| | Cell Line, Tumor | 8 | 2012 | 3540 | 0.270 |
Why?
| | Lymphocyte Activation | 3 | 2009 | 1126 | 0.270 |
Why?
| | Mice, Inbred CFTR | 4 | 2012 | 5 | 0.270 |
Why?
| | Chlorine | 3 | 2015 | 64 | 0.270 |
Why?
| | Gene Expression Regulation | 4 | 2020 | 2608 | 0.270 |
Why?
| | Chromatography, High Pressure Liquid | 5 | 2011 | 594 | 0.260 |
Why?
| | Peroxidase | 4 | 2020 | 168 | 0.260 |
Why?
| | Carrier Proteins | 1 | 2010 | 737 | 0.230 |
Why?
| | Disease Models, Animal | 13 | 2024 | 4557 | 0.230 |
Why?
| | Hippocampus | 5 | 2024 | 965 | 0.230 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2011 | 881 | 0.230 |
Why?
| | Chemokine CXCL1 | 1 | 2025 | 76 | 0.230 |
Why?
| | Chronic Disease | 7 | 2017 | 1813 | 0.230 |
Why?
| | Cisplatin | 1 | 2007 | 334 | 0.220 |
Why?
| | Administration, Oral | 5 | 2021 | 847 | 0.220 |
Why?
| | Epilepsy, Temporal Lobe | 2 | 2015 | 37 | 0.220 |
Why?
| | Microsomes, Liver | 1 | 2005 | 85 | 0.220 |
Why?
| | Stavudine | 1 | 2004 | 6 | 0.220 |
Why?
| | Monocytes | 2 | 2021 | 538 | 0.220 |
Why?
| | Flavins | 1 | 2004 | 4 | 0.210 |
Why?
| | Head and Neck Neoplasms | 1 | 2009 | 558 | 0.210 |
Why?
| | Nucleosides | 1 | 2004 | 25 | 0.210 |
Why?
| | Pulmonary Fibrosis | 1 | 2008 | 395 | 0.200 |
Why?
| | Glutamate-Cysteine Ligase | 3 | 2024 | 20 | 0.200 |
Why?
| | Lipid Peroxidation | 7 | 2007 | 160 | 0.200 |
Why?
| | Neoplasms | 3 | 2014 | 2875 | 0.200 |
Why?
| | Cigarette Smoking | 1 | 2025 | 99 | 0.200 |
Why?
| | Nitric Oxide | 2 | 2025 | 897 | 0.200 |
Why?
| | Pulmonary Edema | 1 | 2003 | 106 | 0.190 |
Why?
| | Bronchoalveolar Lavage | 2 | 2021 | 89 | 0.190 |
Why?
| | Cells, Cultured | 8 | 2018 | 4154 | 0.180 |
Why?
| | DNA Replication | 1 | 2004 | 251 | 0.180 |
Why?
| | Anticonvulsants | 2 | 2017 | 235 | 0.180 |
Why?
| | Vaping | 1 | 2023 | 66 | 0.180 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2002 | 85 | 0.180 |
Why?
| | Electrochemistry | 1 | 2002 | 73 | 0.180 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2025 | 459 | 0.180 |
Why?
| | Lipopolysaccharides | 4 | 2016 | 863 | 0.180 |
Why?
| | Double-Blind Method | 2 | 2017 | 2029 | 0.180 |
Why?
| | Structure-Activity Relationship | 5 | 2012 | 570 | 0.170 |
Why?
| | Brain | 4 | 2018 | 2933 | 0.170 |
Why?
| | Substrate Specificity | 3 | 2013 | 388 | 0.170 |
Why?
| | Pulmonary Alveoli | 2 | 2020 | 383 | 0.170 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2008 | 1129 | 0.170 |
Why?
| | Administration, Inhalation | 3 | 2015 | 574 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2016 | 2027 | 0.170 |
Why?
| | Thiobarbituric Acid Reactive Substances | 4 | 2007 | 29 | 0.160 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 43 | 0.160 |
Why?
| | Burkholderia | 1 | 2020 | 13 | 0.160 |
Why?
| | Oxygen | 4 | 2015 | 995 | 0.160 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2194 | 0.160 |
Why?
| | Cyanates | 1 | 2019 | 4 | 0.160 |
Why?
| | Aging | 2 | 2010 | 1966 | 0.160 |
Why?
| | Adenocarcinoma | 1 | 2007 | 928 | 0.160 |
Why?
| | Selenium Compounds | 1 | 2019 | 18 | 0.150 |
Why?
| | Drug Evaluation, Preclinical | 3 | 2017 | 194 | 0.150 |
Why?
| | Middle Aged | 11 | 2025 | 35875 | 0.150 |
Why?
| | MPTP Poisoning | 2 | 2017 | 6 | 0.150 |
Why?
| | Mice, Hairless | 3 | 2014 | 47 | 0.140 |
Why?
| | Morbidity | 1 | 2020 | 323 | 0.140 |
Why?
| | Particle Size | 1 | 2020 | 411 | 0.140 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 442 | 0.140 |
Why?
| | Isoflurophate | 1 | 2018 | 3 | 0.140 |
Why?
| | Drug Synergism | 3 | 2012 | 357 | 0.140 |
Why?
| | Pseudomonas aeruginosa | 2 | 2015 | 356 | 0.140 |
Why?
| | DNA Damage | 5 | 2009 | 430 | 0.140 |
Why?
| | Interleukin-13 | 1 | 2018 | 144 | 0.130 |
Why?
| | Neurotoxicity Syndromes | 1 | 2018 | 38 | 0.130 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 461 | 0.130 |
Why?
| | Female | 20 | 2025 | 78271 | 0.130 |
Why?
| | Dimercaprol | 1 | 2017 | 6 | 0.130 |
Why?
| | Kinetics | 2 | 2013 | 1627 | 0.130 |
Why?
| | Neutrophils | 3 | 2020 | 1134 | 0.130 |
Why?
| | Antiparkinson Agents | 1 | 2017 | 41 | 0.130 |
Why?
| | Auranofin | 2 | 2013 | 6 | 0.120 |
Why?
| | Catalysis | 3 | 2008 | 322 | 0.120 |
Why?
| | Tumor Cells, Cultured | 2 | 2011 | 919 | 0.120 |
Why?
| | Reactive Nitrogen Species | 2 | 2018 | 16 | 0.120 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2007 | 99 | 0.120 |
Why?
| | Sulfhydryl Compounds | 2 | 2017 | 189 | 0.120 |
Why?
| | Cornea | 2 | 2007 | 155 | 0.110 |
Why?
| | Age Factors | 2 | 2015 | 3333 | 0.110 |
Why?
| | Myocardium | 4 | 2015 | 939 | 0.110 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2015 | 33 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 573 | 0.110 |
Why?
| | Matrix Metalloproteinases | 1 | 2015 | 98 | 0.110 |
Why?
| | Intracellular Space | 2 | 2012 | 66 | 0.110 |
Why?
| | Thiourea | 2 | 2013 | 41 | 0.110 |
Why?
| | Comet Assay | 1 | 2014 | 14 | 0.110 |
Why?
| | NADPH Oxidases | 2 | 2013 | 124 | 0.110 |
Why?
| | Mice, Inbred BALB C | 4 | 2013 | 1253 | 0.110 |
Why?
| | Drug Resistance, Multiple | 1 | 2014 | 25 | 0.110 |
Why?
| | Response Elements | 2 | 2012 | 89 | 0.110 |
Why?
| | Aged | 6 | 2018 | 25913 | 0.110 |
Why?
| | Neurons | 3 | 2018 | 1640 | 0.100 |
Why?
| | Pneumonia, Bacterial | 1 | 2015 | 113 | 0.100 |
Why?
| | DNA-Directed DNA Polymerase | 2 | 2006 | 48 | 0.100 |
Why?
| | Transcription Factor AP-1 | 2 | 2011 | 79 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 100 | 0.100 |
Why?
| | Selenocysteine | 1 | 2013 | 5 | 0.100 |
Why?
| | Pollen | 1 | 2013 | 19 | 0.100 |
Why?
| | Cytoprotection | 2 | 2013 | 55 | 0.100 |
Why?
| | Hypochlorous Acid | 1 | 2013 | 8 | 0.100 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2013 | 44 | 0.100 |
Why?
| | Bronchioles | 1 | 2013 | 29 | 0.100 |
Why?
| | Thioredoxin Reductase 2 | 1 | 2012 | 2 | 0.100 |
Why?
| | Glycolysis | 1 | 2015 | 339 | 0.090 |
Why?
| | Microbial Viability | 1 | 2013 | 90 | 0.090 |
Why?
| | Adult | 8 | 2016 | 40449 | 0.090 |
Why?
| | Liver | 4 | 2024 | 1887 | 0.090 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2010 | 115 | 0.090 |
Why?
| | In Vitro Techniques | 2 | 2005 | 1047 | 0.090 |
Why?
| | Immunohistochemistry | 4 | 2010 | 1716 | 0.090 |
Why?
| | MAP Kinase Signaling System | 2 | 2017 | 310 | 0.090 |
Why?
| | Antigens | 1 | 2014 | 347 | 0.090 |
Why?
| | Bacteria | 1 | 2019 | 889 | 0.090 |
Why?
| | Alveolar Epithelial Cells | 1 | 2013 | 120 | 0.090 |
Why?
| | Amino Acid Substitution | 1 | 2013 | 304 | 0.090 |
Why?
| | Dopaminergic Neurons | 1 | 2012 | 67 | 0.090 |
Why?
| | Biomarkers | 5 | 2018 | 4271 | 0.090 |
Why?
| | Random Allocation | 4 | 2017 | 363 | 0.090 |
Why?
| | Transcriptional Activation | 2 | 2011 | 383 | 0.090 |
Why?
| | Cysteine | 1 | 2013 | 210 | 0.090 |
Why?
| | Asthma | 3 | 2013 | 1767 | 0.090 |
Why?
| | Extracellular Fluid | 1 | 2011 | 36 | 0.090 |
Why?
| | Ischemia | 2 | 2007 | 421 | 0.090 |
Why?
| | Heart Diseases | 1 | 2015 | 349 | 0.090 |
Why?
| | Olfactory Mucosa | 1 | 2011 | 39 | 0.090 |
Why?
| | Antigen-Presenting Cells | 2 | 2009 | 160 | 0.090 |
Why?
| | Phagocytosis | 2 | 2012 | 299 | 0.080 |
Why?
| | Fumarate Hydratase | 2 | 2011 | 3 | 0.080 |
Why?
| | Copper | 2 | 2009 | 113 | 0.080 |
Why?
| | Aconitate Hydratase | 2 | 2011 | 14 | 0.080 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 276 | 0.080 |
Why?
| | Mitochondria, Heart | 3 | 2015 | 102 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 432 | 0.080 |
Why?
| | Blue Cross Blue Shield Insurance Plans | 1 | 2010 | 2 | 0.080 |
Why?
| | Cognition Disorders | 1 | 2015 | 538 | 0.080 |
Why?
| | Nasal Cavity | 1 | 2011 | 62 | 0.080 |
Why?
| | Blood-Brain Barrier | 3 | 2021 | 155 | 0.080 |
Why?
| | Irritants | 1 | 2010 | 38 | 0.080 |
Why?
| | Dopamine | 2 | 2017 | 283 | 0.080 |
Why?
| | Cardiomyopathies | 2 | 2006 | 338 | 0.080 |
Why?
| | Peptide Fragments | 1 | 2014 | 699 | 0.080 |
Why?
| | Apoproteins | 1 | 2009 | 15 | 0.080 |
Why?
| | Bronchi | 1 | 2012 | 267 | 0.080 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 397 | 0.080 |
Why?
| | Dermatitis, Irritant | 1 | 2009 | 9 | 0.080 |
Why?
| | Fluorescent Dyes | 1 | 2011 | 329 | 0.080 |
Why?
| | tert-Butylhydroperoxide | 1 | 2009 | 9 | 0.080 |
Why?
| | Electron Transport | 1 | 2009 | 118 | 0.080 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2009 | 97 | 0.080 |
Why?
| | Heme Oxygenase-1 | 1 | 2009 | 74 | 0.080 |
Why?
| | Fungal Proteins | 1 | 2010 | 145 | 0.070 |
Why?
| | Paraquat | 2 | 2012 | 13 | 0.070 |
Why?
| | HIV Infections | 2 | 2004 | 3154 | 0.070 |
Why?
| | Iron | 2 | 2009 | 359 | 0.070 |
Why?
| | Health Expenditures | 1 | 2010 | 194 | 0.070 |
Why?
| | Demography | 1 | 2009 | 288 | 0.070 |
Why?
| | Biological Transport | 1 | 2010 | 417 | 0.070 |
Why?
| | rho GTP-Binding Proteins | 1 | 2009 | 56 | 0.070 |
Why?
| | Biocatalysis | 1 | 2008 | 69 | 0.070 |
Why?
| | Body Fluids | 1 | 2008 | 70 | 0.070 |
Why?
| | Interferon-gamma | 2 | 2009 | 784 | 0.070 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2008 | 55 | 0.070 |
Why?
| | Benzimidazoles | 1 | 2009 | 190 | 0.070 |
Why?
| | Amino Acids | 2 | 2010 | 521 | 0.070 |
Why?
| | Time Factors | 3 | 2016 | 7173 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2003 | 1985 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 983 | 0.070 |
Why?
| | Self Care | 1 | 2010 | 389 | 0.070 |
Why?
| | Gene Expression | 3 | 2013 | 1490 | 0.070 |
Why?
| | Electron Transport Complex I | 1 | 2007 | 42 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 758 | 0.060 |
Why?
| | Radiation-Protective Agents | 1 | 2007 | 17 | 0.060 |
Why?
| | Neurofibromin 1 | 1 | 2007 | 26 | 0.060 |
Why?
| | Radiation Injuries, Experimental | 1 | 2007 | 20 | 0.060 |
Why?
| | Epilepsy | 1 | 2011 | 376 | 0.060 |
Why?
| | Eye Proteins | 1 | 2007 | 90 | 0.060 |
Why?
| | Fibrosis | 1 | 2009 | 548 | 0.060 |
Why?
| | Antiviral Agents | 2 | 2023 | 767 | 0.060 |
Why?
| | Neurofibromatosis 1 | 1 | 2007 | 54 | 0.060 |
Why?
| | Cell Fractionation | 1 | 2006 | 52 | 0.060 |
Why?
| | Intestinal Absorption | 1 | 2007 | 103 | 0.060 |
Why?
| | Pilocarpine | 2 | 2017 | 16 | 0.060 |
Why?
| | Disease Management | 1 | 2010 | 645 | 0.060 |
Why?
| | Bacterial Proteins | 1 | 2013 | 955 | 0.060 |
Why?
| | HL-60 Cells | 1 | 2006 | 29 | 0.060 |
Why?
| | Mycoplasma Infections | 1 | 2006 | 17 | 0.060 |
Why?
| | Dexamethasone | 2 | 2012 | 372 | 0.060 |
Why?
| | Leukemia, Myeloid | 1 | 2006 | 48 | 0.060 |
Why?
| | Stromal Cells | 1 | 2006 | 124 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2009 | 1173 | 0.060 |
Why?
| | Lens, Crystalline | 1 | 2007 | 136 | 0.060 |
Why?
| | Radiation Injuries | 1 | 2007 | 151 | 0.060 |
Why?
| | Longevity | 1 | 2007 | 173 | 0.060 |
Why?
| | Corpus Striatum | 1 | 2007 | 179 | 0.060 |
Why?
| | Saccharomyces cerevisiae | 1 | 2010 | 579 | 0.060 |
Why?
| | Cytochrome P-450 CYP2B1 | 1 | 2005 | 2 | 0.060 |
Why?
| | Caspase 8 | 1 | 2005 | 47 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 1 | 2005 | 13 | 0.060 |
Why?
| | Young Adult | 3 | 2023 | 14105 | 0.060 |
Why?
| | Quality of Life | 1 | 2017 | 3185 | 0.060 |
Why?
| | Models, Biological | 2 | 2010 | 1821 | 0.050 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2025 | 56 | 0.050 |
Why?
| | Drosophila melanogaster | 1 | 2007 | 236 | 0.050 |
Why?
| | Xenobiotics | 1 | 2005 | 32 | 0.050 |
Why?
| | Cations | 1 | 2005 | 82 | 0.050 |
Why?
| | Aldehydes | 3 | 2012 | 142 | 0.050 |
Why?
| | Nitric Oxide Synthase | 2 | 2003 | 235 | 0.050 |
Why?
| | Oxidoreductases | 1 | 2005 | 96 | 0.050 |
Why?
| | Cysteamine | 1 | 2024 | 7 | 0.050 |
Why?
| | Cataract | 1 | 2007 | 238 | 0.050 |
Why?
| | Ferritins | 1 | 2004 | 69 | 0.050 |
Why?
| | Caspases | 1 | 2005 | 232 | 0.050 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2005 | 162 | 0.050 |
Why?
| | Reperfusion Injury | 1 | 2007 | 300 | 0.050 |
Why?
| | Cell Respiration | 2 | 2015 | 107 | 0.050 |
Why?
| | Liver Diseases | 1 | 2007 | 304 | 0.050 |
Why?
| | Glyoxylates | 1 | 2003 | 8 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2018 | 635 | 0.050 |
Why?
| | Hypertension | 1 | 2012 | 1263 | 0.050 |
Why?
| | Sulfonylurea Compounds | 1 | 2003 | 51 | 0.050 |
Why?
| | Insulin | 1 | 2014 | 2507 | 0.050 |
Why?
| | Liver Circulation | 1 | 2002 | 12 | 0.050 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2009 | 1455 | 0.050 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2023 | 54 | 0.050 |
Why?
| | Half-Life | 2 | 2017 | 151 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2003 | 333 | 0.050 |
Why?
| | Probability | 1 | 2003 | 310 | 0.050 |
Why?
| | Down-Regulation | 1 | 2025 | 627 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 427 | 0.050 |
Why?
| | Adolescent | 3 | 2023 | 22428 | 0.050 |
Why?
| | Disease Progression | 1 | 2010 | 2847 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 187 | 0.050 |
Why?
| | Gene Products, tat | 1 | 2002 | 22 | 0.050 |
Why?
| | Cell Death | 2 | 2015 | 383 | 0.050 |
Why?
| | Hemin | 1 | 2002 | 4 | 0.050 |
Why?
| | Endotoxemia | 1 | 2003 | 87 | 0.050 |
Why?
| | Nitric Acid | 1 | 2002 | 4 | 0.050 |
Why?
| | Molecular Structure | 1 | 2003 | 499 | 0.040 |
Why?
| | Reference Values | 1 | 2003 | 797 | 0.040 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2003 | 278 | 0.040 |
Why?
| | Iraq | 1 | 2021 | 66 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 161 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2005 | 1370 | 0.040 |
Why?
| | Blotting, Western | 3 | 2011 | 1187 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2004 | 1054 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2003 | 245 | 0.040 |
Why?
| | Epithelium | 1 | 2022 | 314 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2003 | 600 | 0.040 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2004 | 370 | 0.040 |
Why?
| | Parkinson Disease | 1 | 2007 | 600 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2021 | 327 | 0.040 |
Why?
| | Eosinophils | 1 | 2003 | 316 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2023 | 340 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 684 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2017 | 766 | 0.040 |
Why?
| | Glutathione Disulfide | 2 | 2011 | 32 | 0.040 |
Why?
| | Estrogens | 1 | 2002 | 380 | 0.040 |
Why?
| | Blood Pressure | 2 | 2003 | 1769 | 0.040 |
Why?
| | Obesity | 1 | 2012 | 3077 | 0.040 |
Why?
| | Soman | 1 | 2018 | 2 | 0.040 |
Why?
| | Tyrosine | 2 | 2011 | 222 | 0.040 |
Why?
| | Brain Ischemia | 1 | 2002 | 358 | 0.040 |
Why?
| | Bronchial Diseases | 1 | 2018 | 38 | 0.040 |
Why?
| | Polyethylene Glycols | 1 | 2024 | 654 | 0.040 |
Why?
| | Prostatic Neoplasms | 1 | 2006 | 974 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 1053 | 0.040 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2018 | 40 | 0.040 |
Why?
| | Cohort Studies | 2 | 2012 | 5960 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2018 | 215 | 0.030 |
Why?
| | Interleukin-8 | 1 | 2018 | 271 | 0.030 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2003 | 410 | 0.030 |
Why?
| | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2017 | 4 | 0.030 |
Why?
| | Mice, Inbred NOD | 2 | 2014 | 610 | 0.030 |
Why?
| | Rotarod Performance Test | 1 | 2017 | 15 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2011 | 162 | 0.030 |
Why?
| | Hemodynamics | 1 | 2002 | 1121 | 0.030 |
Why?
| | T-Lymphocytes | 2 | 2004 | 1982 | 0.030 |
Why?
| | Transfection | 2 | 2012 | 940 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 2017 | 116 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2003 | 916 | 0.030 |
Why?
| | Biological Availability | 1 | 2017 | 142 | 0.030 |
Why?
| | Proteins | 1 | 2003 | 1021 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2017 | 134 | 0.030 |
Why?
| | Nervous System | 1 | 2017 | 70 | 0.030 |
Why?
| | RNA | 1 | 2023 | 940 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 1953 | 0.030 |
Why?
| | Drug Design | 1 | 2017 | 173 | 0.030 |
Why?
| | Microglia | 1 | 2018 | 268 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2003 | 3604 | 0.030 |
Why?
| | Etiocholanolone | 1 | 2015 | 6 | 0.030 |
Why?
| | Nootropic Agents | 1 | 2015 | 30 | 0.030 |
Why?
| | Ranolazine | 1 | 2015 | 25 | 0.030 |
Why?
| | Kainic Acid | 1 | 2015 | 33 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 965 | 0.030 |
Why?
| | Enzyme Inhibitors | 2 | 2012 | 824 | 0.030 |
Why?
| | Acute Kidney Injury | 1 | 2003 | 865 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 95 | 0.030 |
Why?
| | DNA Polymerase gamma | 2 | 2006 | 8 | 0.030 |
Why?
| | Prognosis | 1 | 2003 | 4282 | 0.030 |
Why?
| | RNA, Messenger | 3 | 2012 | 2832 | 0.030 |
Why?
| | Alanine Transaminase | 2 | 2007 | 151 | 0.030 |
Why?
| | Dimerization | 1 | 2014 | 194 | 0.030 |
Why?
| | Military Personnel | 1 | 2021 | 741 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2017 | 519 | 0.030 |
Why?
| | Betula | 1 | 2013 | 3 | 0.020 |
Why?
| | Oxidopamine | 1 | 2012 | 14 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2015 | 251 | 0.020 |
Why?
| | Echocardiography | 2 | 2009 | 652 | 0.020 |
Why?
| | PPAR delta | 1 | 2012 | 6 | 0.020 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 2012 | 23 | 0.020 |
Why?
| | Peroxiredoxins | 1 | 2012 | 26 | 0.020 |
Why?
| | Receptors, Chemokine | 1 | 2012 | 47 | 0.020 |
Why?
| | Interferon-beta | 1 | 2013 | 92 | 0.020 |
Why?
| | Lentivirus | 1 | 2012 | 60 | 0.020 |
Why?
| | Papio | 2 | 2003 | 85 | 0.020 |
Why?
| | Mesencephalon | 1 | 2012 | 64 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2008 | 11679 | 0.020 |
Why?
| | Th2 Cells | 1 | 2013 | 171 | 0.020 |
Why?
| | Motor Activity | 1 | 2017 | 721 | 0.020 |
Why?
| | NF-E2 Transcription Factor, p45 Subunit | 1 | 2012 | 3 | 0.020 |
Why?
| | Emphysema | 1 | 2013 | 100 | 0.020 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2012 | 20 | 0.020 |
Why?
| | Coenzyme A | 1 | 2011 | 7 | 0.020 |
Why?
| | Adenine Nucleotides | 1 | 2011 | 21 | 0.020 |
Why?
| | Holoenzymes | 1 | 2012 | 25 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1030 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 152 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 336 | 0.020 |
Why?
| | Cell Division | 2 | 2004 | 766 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2004 | 2168 | 0.020 |
Why?
| | NAD | 1 | 2011 | 81 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2014 | 3890 | 0.020 |
Why?
| | Receptors, Glucocorticoid | 1 | 2012 | 138 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2012 | 275 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 200 | 0.020 |
Why?
| | Buthionine Sulfoximine | 1 | 2010 | 9 | 0.020 |
Why?
| | Prospective Studies | 1 | 2003 | 7990 | 0.020 |
Why?
| | Dermatitis | 1 | 2010 | 18 | 0.020 |
Why?
| | Skinfold Thickness | 1 | 2010 | 43 | 0.020 |
Why?
| | Sputum | 1 | 2012 | 308 | 0.020 |
Why?
| | Pennsylvania | 1 | 2010 | 138 | 0.020 |
Why?
| | Insurance Claim Review | 1 | 2010 | 83 | 0.020 |
Why?
| | Myocytes, Cardiac | 1 | 2015 | 556 | 0.020 |
Why?
| | Deoxyadenosines | 1 | 2009 | 8 | 0.020 |
Why?
| | Oncogene Protein v-akt | 1 | 2009 | 22 | 0.020 |
Why?
| | Cyclic N-Oxides | 1 | 2009 | 33 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2012 | 744 | 0.020 |
Why?
| | Oxygen Consumption | 2 | 2002 | 724 | 0.020 |
Why?
| | Heart Ventricles | 2 | 2006 | 760 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2011 | 902 | 0.020 |
Why?
| | Mice, Inbred ICR | 1 | 2009 | 113 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1306 | 0.020 |
Why?
| | Mice, Transgenic | 2 | 2006 | 2182 | 0.020 |
Why?
| | Fibroblasts | 2 | 2006 | 1034 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2009 | 124 | 0.020 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2009 | 76 | 0.020 |
Why?
| | Phenotype | 2 | 2007 | 3162 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 547 | 0.020 |
Why?
| | Electroencephalography | 1 | 2011 | 532 | 0.020 |
Why?
| | rho-Associated Kinases | 1 | 2009 | 83 | 0.020 |
Why?
| | Oxidative Phosphorylation | 1 | 2009 | 210 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2012 | 535 | 0.020 |
Why?
| | Cerebral Cortex | 1 | 2011 | 464 | 0.020 |
Why?
| | Indoles | 1 | 2012 | 501 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2010 | 634 | 0.020 |
Why?
| | Cell Cycle | 1 | 2010 | 596 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2007 | 29 | 0.020 |
Why?
| | Nitrosation | 1 | 2007 | 8 | 0.020 |
Why?
| | Membrane Lipids | 1 | 2007 | 83 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2007 | 164 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2007 | 85 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1618 | 0.020 |
Why?
| | Mitomycin | 1 | 2006 | 32 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2012 | 935 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 2007 | 268 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2007 | 209 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 320 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 159 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2007 | 250 | 0.010 |
Why?
| | Lung Volume Measurements | 1 | 2006 | 46 | 0.010 |
Why?
| | Etoposide | 1 | 2006 | 166 | 0.010 |
Why?
| | NF-kappa B | 1 | 2009 | 661 | 0.010 |
Why?
| | Protein Binding | 2 | 2002 | 2273 | 0.010 |
Why?
| | Internet | 1 | 2010 | 699 | 0.010 |
Why?
| | Heart | 1 | 2009 | 636 | 0.010 |
Why?
| | Rabbits | 1 | 2006 | 648 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1496 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 779 | 0.010 |
Why?
| | Radioisotopes | 1 | 2004 | 33 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 388 | 0.010 |
Why?
| | fas Receptor | 1 | 2004 | 92 | 0.010 |
Why?
| | Phagocytes | 1 | 2004 | 81 | 0.010 |
Why?
| | Renal Blood Flow, Effective | 1 | 2003 | 1 | 0.010 |
Why?
| | Antigen Presentation | 1 | 2004 | 205 | 0.010 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 1 | 2003 | 9 | 0.010 |
Why?
| | Mutation | 2 | 2006 | 4089 | 0.010 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2003 | 76 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 396 | 0.010 |
Why?
| | Injections, Intraventricular | 1 | 2002 | 56 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2003 | 76 | 0.010 |
Why?
| | DNA Polymerase beta | 1 | 2002 | 6 | 0.010 |
Why?
| | Guinea Pigs | 1 | 2002 | 159 | 0.010 |
Why?
| | Kupffer Cells | 1 | 2002 | 53 | 0.010 |
Why?
| | Cerebral Infarction | 1 | 2002 | 47 | 0.010 |
Why?
| | Carotid Artery, Internal | 1 | 2002 | 45 | 0.010 |
Why?
| | Permeability | 1 | 2003 | 168 | 0.010 |
Why?
| | Estrone | 1 | 2002 | 40 | 0.010 |
Why?
| | DNA Polymerase I | 1 | 2002 | 31 | 0.010 |
Why?
| | Linoleic Acid | 1 | 2002 | 44 | 0.010 |
Why?
| | Atrial Natriuretic Factor | 1 | 2002 | 57 | 0.010 |
Why?
| | Ions | 1 | 2002 | 71 | 0.010 |
Why?
| | Respiratory Burst | 1 | 2002 | 18 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2002 | 140 | 0.010 |
Why?
| | Isoelectric Focusing | 1 | 2002 | 30 | 0.010 |
Why?
| | S-Nitrosoglutathione | 1 | 2002 | 8 | 0.010 |
Why?
| | PC12 Cells | 1 | 2002 | 42 | 0.010 |
Why?
| | Gene Targeting | 1 | 2002 | 82 | 0.010 |
Why?
| | Insulinoma | 1 | 2002 | 28 | 0.010 |
Why?
| | Free Radicals | 1 | 2002 | 110 | 0.010 |
Why?
| | Membrane Potentials | 1 | 2003 | 280 | 0.010 |
Why?
| | Electrons | 1 | 2002 | 88 | 0.010 |
Why?
| | Hyperoxia | 1 | 2003 | 99 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2002 | 415 | 0.010 |
Why?
| | Clone Cells | 1 | 2002 | 266 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 292 | 0.010 |
Why?
| | Organ Specificity | 1 | 2002 | 312 | 0.010 |
Why?
| | Dogs | 1 | 2002 | 437 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2002 | 223 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 151 | 0.010 |
Why?
| | Hormone Replacement Therapy | 1 | 2002 | 106 | 0.010 |
Why?
| | Mice, SCID | 1 | 2002 | 369 | 0.010 |
Why?
| | Gene Rearrangement | 1 | 2002 | 155 | 0.010 |
Why?
| | Models, Chemical | 1 | 2002 | 269 | 0.010 |
Why?
| | Ascorbic Acid | 1 | 2002 | 180 | 0.010 |
Why?
| | Myocardial Contraction | 1 | 2002 | 298 | 0.010 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2002 | 198 | 0.010 |
Why?
| | Occupational Exposure | 1 | 2004 | 354 | 0.010 |
Why?
| | Hepatectomy | 1 | 2002 | 273 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 2003 | 458 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 851 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 2155 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 1000 | 0.010 |
Why?
| | Swine | 1 | 2002 | 833 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2003 | 760 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2930 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2002 | 750 | 0.010 |
Why?
| | Aorta | 1 | 2002 | 429 | 0.010 |
Why?
| | Fatty Acids | 1 | 2002 | 450 | 0.010 |
Why?
| | Electrocardiography | 1 | 2002 | 662 | 0.010 |
Why?
| | Estradiol | 1 | 2002 | 533 | 0.010 |
Why?
| | Fetus | 1 | 2003 | 803 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2002 | 668 | 0.010 |
Why?
| | Survival Rate | 1 | 2003 | 2089 | 0.010 |
Why?
| | Calcium | 1 | 2002 | 1183 | 0.010 |
Why?
| | Kidney | 1 | 2003 | 1495 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3863 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2010 | 17066 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2002 | 1795 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2003 | 6429 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2452 | 0.000 |
Why?
|
|
Day's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|